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aTATE-OF-THE-ART PAPER1903The Importance of the RV in Adult CHDarole A. Warnes
he importance of the right ventricle (RV) in congenital heart disease (CHD) is reviewed by
arnes. The RV has a remarkable ability to adapt to pressure and volume load, but its size
nd function are often overlooked. Patients with various forms of CHD may develop
ymptoms only after RV dysfunction has occurred, at which point they are at risk for lethal
entricular arrhythmias, and surgical outcomes are less favorable. Appropriate imaging of the
ize and function of the RV is reviewed and the conclusion is that adults with CHD should
e followed at centers that have expertise in these issues to optimize outcomes.TATE-OF-THE-ART PAPERAdult Sequelae of Kawasaki Disease1911ohn B. Gordon, Andrew M. Kahn, Jane C. Burns
1921alton M. Gersony
awasaki disease (KD) is an acute, self-limited vasculitis that typically occurs in young
hildren and was first described in 1967. It is currently believed to result from an unknown
nfectious trigger in patients with a genetic susceptibility. KD is the most common cause of
cquired heart disease in the pediatric age group in developed countries. Gordon and
olleagues review the natural history of KD, which can result in not only aneurysmal coronary
rtery dilations but also valvulitis and myocarditis. The damage to the heart may have the
otential to result in several complications approximately 20 years later that adult cardiologists
hould be aware of, and are reviewed in this paper. In an accompanying commentary,
ersony points out that definitive late clinical coronary manifestations have not been reported
n any series of KD patients who had small aneurysms or no significant coronary involvement
oted during the acute illness. Since, in the modern era such individuals make up over 97%
f the emerging post-KD population, he cautions against generating unnecessary lifetime
nxiety.(continued on page A-24)
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ENTERVENTIONAL CARDIOLOGY1924Incidence and Predictors of DES Fractureaku Nakazawa, Aloke V. Finn, Marc Vorpahl, Elena Ladich, Robert Kutys, Isidora Balazs,
rank D. Kolodgie, Renu Virmani
linically the incidence of stent fracture with drug-eluting stents (DES) is reported to be 1%
o 2%; however, the true incidence may be underestimated because of the limited sensitivity
f angiography to detect these fractures. Nakazawa and colleagues studied hearts obtained at
utopsy from patients who had previously received a DES. Stent fracture was graded on a
cale and was found in 29% of the stents. Stent fracture was more likely in older stents,
onger stents, Cypher (Cordis Corp., Miami Lakes, Florida) compared with Taxus (Boston
cientific, Natick, Massachusetts) stents, and in overlapping stents. While simple fractures did
ot appear to be clinically detrimental, two-thirds of the stents with transection of the struts
ausing a gap in stent segment were associated with thrombosis or restenosis. This study
uggests that the true incidence of stent fracture is much higher than 1% to 2% and may be
linically relevant.ditorial Comment: Andrew J. Carter, p. 1932NTITHROMBOTIC THERAPY1935No Difference in Clopidogrel Efficacy/Safety Between Women and Meneffrey S. Berger, Deepak L. Bhatt, Christopher P. Cannon, Zhengming Chen, Lixin Jiang, James B. Jones,
hamir R. Mehta, Marc S. Sabatine, Steven R. Steinhubl, Eric J. Topol, Peter B. Berger
erger and colleagues investigated whether there were differences in the clinical benefits of
lopidogrel for men and women by performing a meta-analysis of all large trials that
andomized subjects to clopidogrel or placebo. These trials included 80,000 subjects, 30% of
hom were female. The overall reduction in cardiovascular events was similar for men and
omen. However, in women the risk reduction was only significant for myocardial infarction
odds ratio [OR]: 0.81) and was not statistically significant for stroke (OR: 0.91) or total
eath (OR: 0.99), although there were significant reductions in men. Clopidogrel increased
he risk of major bleeding in both women (OR: 1.43) and men (OR: 1.22) similarly.
lopidogrel reduces the risk of cardiovascular events in both women and men but the nature
f the benefits is somewhat altered.
ditorial Comment: David P. Faxon, p. 1946(continued on page A-28)
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EARDIAC IMAGING AND STENT FAILURE1949Stent Gap: Detectable by CTA, Linked to In-Stent Restenosisarvey S. Hecht, Sotir Polena, Vladimir Jelnin, Marcelo Jimenez, Tandeep Bhatti, Manish Parikh,
eorgia Panagopoulos, Gary Roubin
his study by Hecht and colleagues used computed tomographic angiography (CTA) to
tudy the incidence and pathogenesis of stent fracture with drug-eluting stents. CTA studies
ere performed on almost 300 subjects with over 600 stents. Stent gap was diagnosed when
oth of the following criteria were fulfilled: 1) partial or complete (circumferential) gap or a
crush” pattern on visual inspection; and 2) confirmation of Hounsfield units 300 at the site
f separation, consistent with the absence of metallic material. In patients who had both
atheter coronary angiography (CCA) and CTA, stent gap was noted in 16.9% by CTA but
nly 1.0% by CCA. In-stent restenosis was noted in 46% of the stent gaps, and stent gap
etected by CTA accounted for 28% of the cases of in-stent restenosis. CTA appears to be a
owerful tool for understanding the relationship between stent fracture and in-stent
estenosis.ALVULAR HEART DISEASE
1961VESD >40 mm Predicts Poor Outcomes in Patients With
Flail Mitral Leaflets CMEhristophe Tribouilloy, Francesco Grigioni, Jean François Avierinos, Andrea Barbieri, Dan Rusinaru,
atherine Szymanski, Marinella Ferlito, Laurence Tafanelli, Francesca Bursi, Faouzi Trojette,
ngelo Branzi, Gilbert Habib, Maria G. Modena, Maurice Enriquez-Sarano, on behalf of the
IDA Investigators
ribouilloy and colleagues analyzed the association between left ventricular end-systolic
iameter (LVESD) and survival after diagnosis in patients with organic mitral regurgitation
MR) due to flail leaflets in a registry that has enrolled almost 800 subjects. LVESD 40
m independently predicted overall (hazard ratio [HR]: 1.95) and cardiac mortality (HR:
.09) under conservative management. During the entire follow-up (including post-surgical),
VESD 40 mm independently predicted cardiac mortality due to persistence of excess
ortality after surgery (HR: 1.81). In MR due to flail leaflets, LVESD 40 mm is
ndependently associated with increased mortality under medical management but also after
urgical correction, suggesting that patients should be operated before LVESD reaches 40 mm.
ditorial Comment: Luc A. Pierard, Julien Magne, p. 1969(continued on page A-32)
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iULMONARY HYPERTENSION1971Prolonged Benefit for Ambrisentan in Patients With PAHonald J. Oudiz, Nazzareno Galiè, Horst Olschewski, Fernando Torres, Adaani Frost, Hossein A. Ghofrani,
avid B. Badesch, Michael D. McGoon, Vallerie V. McLaughlin, Ellen B. Roecker, Brooke C. Harrison,
arrin Despain, Christopher Dufton, Lewis J. Rubin, for the ARIES Study Group
his study evaluated the long-term safety and efficacy of ambrisentan in almost 400 patients
ith pulmonary arterial hypertension (PAH). For this study, all subjects received ambrisentan
ut at varying doses. After 2 years, the mean change from baseline in 6-min walk distance
as improved for the 5- and 10-mg groups. The rates of survival and freedom from clinical
orsening were better than predicted for this cohort of patients. The annualized risk of
minotransferase abnormalities 3 the upper limit of normal was 2% per year, similar to
he rate of abnormalities seen with placebo treatment in this type of patient. Two years of
mbrisentan treatment was associated with sustained improvements in exercise capacity and a
ow risk of clinical worsening and death in patients with PAH.ARDIOVASCULAR RISK1982Left Atrial Enlargement Linked to Both Hypertension and Obesityan Stritzke, Marcello Ricardo Paulista Markus, Stefanie Duderstadt, Wolfgang Lieb, Andreas Luchner,
ngela Döring, Ulrich Keil, Hans-Werner Hense, Heribert Schunkert, for the MONICA/KORA Investigators
lthough left atrial enlargement (LAE) is an independent risk factor for atrial fibrillation,
troke, and death, little information is available about the determinants of left atrial (LA) size.
tritzke and colleagues performed a prospective study of over 1,000 subjects with LA volume
etermined by standardized echocardiography at baseline and again after 10 years. LA volume
as indexed to body height (iLA) and LAE was defined as iLA 35.7 and 33.7 ml/m in
en and women, respectively. At baseline, the prevalence of LAE was 9.8%. Both obesity
nd hypertension were independent predictors of LAE. Adjusted mean values for iLA were
ignificantly lower in normal weight hypertensive patients than in obese normotensive patients
ith the highest iLA in the obese hypertensive subgroup. Obesity appears to be the most
mportant risk factor for LAE.
